Clinical Trials Logo

Stage II Skin Cancer clinical trials

View clinical trials related to Stage II Skin Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04315701 Recruiting - Clinical trials for Recurrent Skin Squamous Cell Carcinoma

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Start date: June 17, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or has spread regionally (regionally advanced), and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.